Corrin Ring Conjugation in Peptide Drug Development - A Brief History of 'Corrination'.

IF 3.6 4区 医学 Q2 CHEMISTRY, MEDICINAL
ChemMedChem Pub Date : 2025-03-13 DOI:10.1002/cmdc.202500129
Robert P Doyle, Nancy Cham
{"title":"Corrin Ring Conjugation in Peptide Drug Development - A Brief History of 'Corrination'.","authors":"Robert P Doyle, Nancy Cham","doi":"10.1002/cmdc.202500129","DOIUrl":null,"url":null,"abstract":"<p><p>Recently, we coined the term 'corrination' to describe the conjugate modification of a peptide, protein, small molecule, or radionuclide with a corrin ring-containing molecule.  By exploiting the innate chemico-physical properties of corrin ring-containing compounds, both in general and specifically via the innate dietary B12 uptake pathway in mammals, corrination has been explored for drug development and targeted/localized delivery of probes and therapeutics. Most recently, it is in the field of peptide-based therapeutics that corrination is generating significant interest. Peptide-based drugs possess several limitations that restrict their clinical application, including poor solubility and stability, low oral bioavailability, and negative side effects often due to drug distribution. Therefore, methods must be developed to address these issues without affecting the peptide's functionality. In this review, we describe the design and synthetic approaches to peptide corrination, along with examples, which demonstrate the broad applicability of the technique, namely 1) mitigated peptide aggregation, 2) improved protection against proteolysis, 3) reduced side effects via targeted localization 4) regioselective production of peptide disulfide bonds, 5) improved oral drug absorption. We describe how corrination offers a facile route to improving peptide pharmacokinetic and pharmacodynamic properties, making this a useful platform technology in the field of peptide drug development.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202500129"},"PeriodicalIF":3.6000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cmdc.202500129","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Recently, we coined the term 'corrination' to describe the conjugate modification of a peptide, protein, small molecule, or radionuclide with a corrin ring-containing molecule.  By exploiting the innate chemico-physical properties of corrin ring-containing compounds, both in general and specifically via the innate dietary B12 uptake pathway in mammals, corrination has been explored for drug development and targeted/localized delivery of probes and therapeutics. Most recently, it is in the field of peptide-based therapeutics that corrination is generating significant interest. Peptide-based drugs possess several limitations that restrict their clinical application, including poor solubility and stability, low oral bioavailability, and negative side effects often due to drug distribution. Therefore, methods must be developed to address these issues without affecting the peptide's functionality. In this review, we describe the design and synthetic approaches to peptide corrination, along with examples, which demonstrate the broad applicability of the technique, namely 1) mitigated peptide aggregation, 2) improved protection against proteolysis, 3) reduced side effects via targeted localization 4) regioselective production of peptide disulfide bonds, 5) improved oral drug absorption. We describe how corrination offers a facile route to improving peptide pharmacokinetic and pharmacodynamic properties, making this a useful platform technology in the field of peptide drug development.

求助全文
约1分钟内获得全文 求助全文
来源期刊
ChemMedChem
ChemMedChem 医学-药学
CiteScore
6.70
自引率
2.90%
发文量
280
审稿时长
1 months
期刊介绍: Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信